AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models

被引：0
|
作者：
Mak, Baldwin C. [1 ]
McConkey, Fortunata [1 ]
Feng, Ningping [1 ]
O'Reilly, Kevin [1 ]
Rubinstein, Daniel [1 ]
Kasprzyk, Philip G. [1 ]
Hahn, Susan E. [1 ]
Pereira, Daniel S. [1 ]
Findlay, Helen [1 ]
Young, David S. [1 ]
机构：
[1] Arius Res Inc, Toronto, ON M5J 1R7, Canada
来源：
MOLECULAR IMMUNOLOGY | 2007年 / 44卷 / 16期
关键词：
D O I：
10.1016/j.molimm.2007.06.094
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：3948 / 3949
页数：2
相关论文
共 15 条
  • [1] AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models
    Mak, Baldwin C.
    McConkey, Fortunata
    Feng, Ningping
    O'Reilly, Kevin
    Kasprzyk, Philip G.
    Rubinstein, Daniel
    Hahn, Susan E.
    Pereira, Daniel S.
    Findlay, Helen
    Young, David S.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3357S - 3358S
  • [2] A monoclonal antibody (AR36A36.11.1) with potent in vivo efficacy in multiple human cancer models targets CD59
    Mak, B.
    McConkey, F.
    Feng, N.
    O'Reilly, K.
    Fung, S. W.
    Wang, M.
    Chau, S.
    Hahn, S. E.
    Pereira, D. S.
    Young, D. S.
    [J]. EJC SUPPLEMENTS, 2008, 6 (12): : 164 - 164
  • [3] Two antibodies directed at complement activation regulating protein CD59 exhibit efficacy in multiple human cancer models
    Rogers, Kristian J.
    Da Cruz, Luis A. G.
    Harris, Valerie
    Fung, Sui-Wah
    Ferry, Alison
    McConkey, Fortunata
    Young, David S.
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [4] A monoclonal antibody targeting Trop-2 exhibits anti-tumor efficacy in human cancer models as a monotherapy and demonstrates efficacy in combination therapy
    Truong, A. H. L.
    Wang, M.
    Harris, V.
    Aziz, N.
    Grabell, J.
    Popp, L.
    Amoozgar, M.
    Hahn, S. E.
    Pereira, D. S.
    Young, D. S.
    [J]. EJC SUPPLEMENTS, 2008, 6 (12): : 165 - 165
  • [5] A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma
    Yu, Tengteng
    Chaganty, Bharat
    Lin, Liang
    Xing, Lijie
    Ramakrishnan, Boopathy
    Wen, Kenneth
    Hsieh, Phillip A.
    Wollacott, Andrew
    Viswanathan, Karthik
    Adari, Hedy
    Cho, Shih-Feng
    Li, Yuyin
    Yang, Wenjuan
    Chen, Hailin
    Xu, Yan
    An, Gang
    Qiu, Lugui
    Munshi, Nikhil C.
    Babcock, Gregory
    Shriver, Zach
    Myette, James
    Anderson, Kenneth
    Tai, Yu-Tzu
    [J]. BLOOD, 2020, 136
  • [6] AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models
    Truong, Amandine H. L.
    Feng, Ningping
    Sayegh, Daad
    Mak, Baldwin C.
    O'Reilly, Kevin
    Fung, Sui-Wah
    Ceric, Nives
    Hahn, Susan H.
    Pereira, Daniel
    Findlay, Helen
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3334S - 3334S
  • [7] Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
    Horton, Holly M.
    Bernett, Matthew J.
    Peipp, Matthias
    Pong, Erik
    Karki, Sher
    Chu, Seung Y.
    Richards, John O.
    Chen, Hsing
    Repp, Roland
    Desjarlais, John R.
    Zhukovsky, Eugene A.
    [J]. BLOOD, 2010, 116 (16) : 3004 - 3012
  • [8] ATSP-7041, a Dual MDM2 and MDMX Targeting Stapled A-helical Peptide Exhibits Potent in Vitro and in Vivo Efficacy in Xenograft Models of Human Cancer
    Chang, Y.
    Graves, B.
    Guerlavais, V.
    Vassilev, L.
    Packman, K.
    Olson, K.
    Annis, A.
    Tovar, C.
    Nash, H.
    Sawyer, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 68 - 69
  • [9] MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds
    Boxhammer, Rainer
    Weirather, Johannes
    Steidl, Stefan
    Endell, Jan
    [J]. BLOOD, 2015, 126 (23)
  • [10] Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models
    Whiteman, Kathleen R.
    Johnson, Holly A.
    Mayo, Michele F.
    Audette, Charlene A.
    Carrigan, Christina N.
    LaBelle, Alyssa
    Zukerberg, Lawrence
    Lambert, John M.
    Lutz, Robert J.
    [J]. MABS, 2014, 6 (02) : 556 - 566
12